Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer.

Journal: Prostate international
Published Date:

Abstract

BACKGROUND: Preclinical and retrospective data suggest that cytoreductive radical prostatectomy may benefit a subset of men who present with metastatic prostate cancer (mPCa). Herein, we report the results of the first planned Phase 1 study on cytoreductive surgery.

Authors

  • Bertram E Yuh
    Division of Urology and Urologic Oncology, City of Hope National Medical Center, Duarte, CA, USA.
  • Young Suk Kwon
    Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Division of Urology, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Brian M Shinder
    Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Division of Urology, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Eric A Singer
    Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Division of Urology, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Thomas L Jang
    Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Division of Urology, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Sinae Kim
    Department of Biostatistics, Rutgers School of Public Health, The State University of New Jersey, New Brunswick, NJ, USA.
  • Mark N Stein
    Department of Internal Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Tina Mayer
    Department of Internal Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Anna Ferrari
    Department of Internal Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Nara Lee
    Department of Internal Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Rahul R Parikh
    Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Nora Ruel
    Division of Urology and Urologic Oncology, City of Hope National Medical Center, Duarte, CA, USA.
  • Wun-Jae Kim
    Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea.
  • Shigeo Horie
    Department of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Seok-Soo Byun
    Department of Urology, Seoul National University Bundang Hospital, Bundang, Korea.
  • Thomas E Ahlering
    Department of Urology, University of California Irvine, Orange, CA, USA.
  • Isaac Yi Kim
    Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Division of Urology, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.

Keywords

No keywords available for this article.